Press Release
03.07.2008
biolitec AG joins the GEX®, the German Stock Exchange index for SMEs
On the June 2008 qualifying date, biolitec stock fulfilled the rigorous selection criteria of the German Entrepreneurial Index – The high-quality segment of the German Stock Exchange is of particular interest to institutional investors – According to Börse Online, biolitec AG is among the 30 most profitable companies in Germany
Jena, July 3, 2008 – The Center for Entrepreneurial and Financial Studies (CEFS), in consultation with the German Stock Exchange, decided in favour of admitting biolitec AG (listed in the Prime Standard of the Frankfurt Stock Exchange under ISIN DE0005213409) to the German Entrepreneurial Index (GEX®) as of the qualifying date in June 2008.
biolitec AG succeeded in meeting the rigorous requirements for joining this high-quality segment of the German Stock Exchange at the quarterly review of the selection criteria. As well as a listing in the Prime Standard and on the German Stock Exchange for a maximum of 10 years, owner dominance is considered an important qualifying condition. The GEX® comprises companies that are run by their owners, who must hold at least 25 percent of company shares. “Qualifying for the GEX® will enhance the reputation of biolitec stock and boost the quality of investment for our shareholders”, commented Dr. Neuberger, CEO of biolitec AG.
The Jena-based company was ranked as one of the 30 most profitable companies in Germany in issue 26 of Börse Online, the independent weekly investor's magazine (dated June 16, 2008). With an operating margin of 14.25%, biolitec AG is on a par with high-profile German companies listed on the DAX and MDAX. According to Dr. Wolfgang Neuberger, “Our rating in Börse Online demonstrates that biolitec AG is a highly profitable company with excellent prospects for growth in the medium term. At the current price level, biolitec stock has enormous potential, even if, as already announced, this year's results will fall short of those achieved last year due to market conditions and currency-related reasons”.
About biolitec
biolitec is the only supplier for photodynamic therapy worldwide that offers all relevant core competencies – photosensitizers, lasers and optical fibers. Besides minimally invasive laser treatments and in the oncology business, biolitec has successfully developed competencies in the field of aesthetics. biolitec is listed in the Prime Standard under ISIN DE0005213409. For more information, please visit www. biolitec.de.